In a study conducted at the Ovarian Cancer Research Foundation (OCRF) at Monash
Medical Centre in Melbourne, an antibody detection method developed by Biosceptre
successfully identified 100% of the invasive ovarian carcinomas (malignant cancers of
the ovaries) included in the tissue analysis.
- Forums
- ASX - By Stock
- ovarian cancer breakthrough
PTD
unknown
In a study conducted at the Ovarian Cancer Research Foundation...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online